financetom
Business
financetom
/
Business
/
Major US Pharmacy Benefit Managers Inflated Drug Prices for Over $7.3 Billion Gain, FTC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Major US Pharmacy Benefit Managers Inflated Drug Prices for Over $7.3 Billion Gain, FTC Says
Jan 14, 2025 9:08 AM

11:59 AM EST, 01/14/2025 (MT Newswires) -- UnitedHealth Group's ( UNH ) OptumRx, CVS Health's ( CVS ) Caremark Rx and Cigna's ( CI ) Express Scripts marked up a number of specialty generic drugs at their affiliated pharmacies by hundreds or thousands of percent, the US Federal Trade Commission said Tuesday.

The practice allowed the three pharmacy benefit managers and their affiliated specialty pharmacies to generate revenue of more than $7.3 billion from dispensing drugs in excess of their projected acquisition costs from 2017 to 2022, the FTC said.

UnitedHealth ( UNH ), CVS and Cigna ( CI ) didn't immediately respond to MT Newswires' requests for comment.

Price: 537.34, Change: -3.80, Percent Change: -0.70

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Deutsche Bank Now Sees Chile's Central Bank Cutting The Policy Rate by 25bps in September
Deutsche Bank Now Sees Chile's Central Bank Cutting The Policy Rate by 25bps in September
Aug 20, 2024
07:17 AM EDT, 08/20/2024 (MT Newswires) -- The Chilean Central Bank (BCCh) will announce its monetary policy decision on Sept. 3 and Deutsche Bank revised its call and now expects the BBCh to reduce the policy rate by 25 bps, setting it at 5.50%. The bank remains of the view that a more prudent course of action would imply waiting...
Medtronic lifts profit forecast on medical devices demand, new launches
Medtronic lifts profit forecast on medical devices demand, new launches
Aug 20, 2024
(Reuters) -Medtronic ( MDT ) slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches. Over the past few quarters, medical device makers have been benefiting from elevated demand for non-urgent surgeries, since patients are increasingly opting for procedures deferred during the pandemic. The...
Medtronic's Fiscal Q1 Adjusted Earnings, Revenue Rise; Raises Fiscal 2025 Guidance
Medtronic's Fiscal Q1 Adjusted Earnings, Revenue Rise; Raises Fiscal 2025 Guidance
Aug 20, 2024
07:12 AM EDT, 08/20/2024 (MT Newswires) -- Medtronic ( MDT ) reported fiscal Q1 adjusted diluted earnings Tuesday of $1.23 per share, up from $1.20 a year earlier. Analysts polled by Capital IQ expected $1.20. Revenue for the quarter ended July 26 was $7.92 billion, compared with $7.70 billion a year earlier. Analysts surveyed by Capital IQ expected $7.90 billion....
XPeng projects lower-than-expected quarterly revenue on stiff competition
XPeng projects lower-than-expected quarterly revenue on stiff competition
Aug 20, 2024
Aug 20 (Reuters) - Chinese firm XPeng ( XPEV ) forecast third-quarter revenue below analysts' expectations and missed June-quarter sales estimates on Tuesday, hurt by stiff competition and a drop in demand for its aging line-up of pricey electric vehicles. The company, however, expects to deliver between 41,000 and 45,000 vehicles in the third quarter, slightly above 40,008 units a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved